Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRNANASDAQ:INMBNYSE:PRMENASDAQ:TIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRNAGreenLight Biosciences$0.30$0.30$0.18▼$5.90$45.43M1.44486,986 shs732 shsINMBINmune Bio$7.46+1.4%$7.51$4.32▼$10.50$171.46M1.63266,449 shs368,959 shsPRMEPrime Medicine$1.22-3.6%$1.45$1.11▼$8.14$154.93M1.91.33 million shs1.35 million shsTILInstil Bio$26.08-14.1%$16.54$9.62▼$92.00$171.06M1.78155,161 shs811,034 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRNAGreenLight Biosciences0.00%0.00%0.00%0.00%0.00%INMBINmune Bio0.00%+2.19%-1.71%-7.10%-22.69%PRMEPrime Medicine0.00%-5.81%-30.17%-51.79%-81.42%TILInstil Bio0.00%+24.07%+106.82%+29.75%+146.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGRNAGreenLight BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AINMBINmune Bio1.8364 of 5 stars3.60.00.00.02.71.70.6PRMEPrime Medicine3.905 of 5 stars4.40.00.00.03.03.31.3TILInstil Bio3.4263 of 5 stars3.54.00.00.01.93.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRNAGreenLight Biosciences 0.00N/AN/AN/AINMBINmune Bio 3.17Buy$22.80205.63% UpsidePRMEPrime Medicine 2.75Moderate Buy$10.08729.90% UpsideTILInstil Bio 3.00Buy$112.33330.73% UpsideCurrent Analyst Ratings BreakdownLatest GRNA, TIL, PRME, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025PRMEPrime MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $1.505/22/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$110.00 ➝ $105.005/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/19/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.003/20/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.003/19/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/18/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.00 ➝ $13.003/5/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.00 ➝ $110.003/3/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRNAGreenLight Biosciences$10.20M4.45N/AN/A$0.32 per share0.94INMBINmune Bio$50K3,429.21N/AN/A$2.07 per share3.60PRMEPrime Medicine$3.85M41.48N/AN/A$1.37 per share0.89TILInstil BioN/AN/AN/AN/A$34.72 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRNAGreenLight Biosciences-$167.05M-$1.14N/A∞N/A-1,521.00%-374.26%-122.78%N/AINMBINmune Bio-$30.01M-$1.93N/AN/AN/AN/A-117.48%-78.96%8/7/2025 (Estimated)PRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/ATILInstil Bio-$156.09M-$11.97N/AN/AN/AN/A-37.44%-25.08%8/12/2025 (Estimated)Latest GRNA, TIL, PRME, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025TILInstil Bio-$2.02-$4.32-$2.30-$4.32N/AN/A5/8/2025Q1 2025INMBINmune Bio-$0.43-$0.43N/A-$0.43N/A$0.05 million3/27/2025Q4 2024INMBINmune Bio-$0.54-$0.40+$0.14-$0.40N/AN/A3/7/2025Full YearPRMEPrime MedicineN/A-$1.65N/AN/AN/AN/A3/4/2025Q4 2024TILInstil Bio-$3.75-$1.82+$1.93-$1.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRNAGreenLight BiosciencesN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/APRMEPrime Medicine$1.45119.01%N/AN/A N/ATILInstil BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRNAGreenLight Biosciences0.491.211.21INMBINmune BioN/A2.592.59PRMEPrime MedicineN/A6.506.50TILInstil Bio0.4712.9012.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRNAGreenLight Biosciences24.41%INMBINmune Bio12.72%PRMEPrime Medicine70.37%TILInstil Bio60.56%Insider OwnershipCompanyInsider OwnershipGRNAGreenLight Biosciences30.30%INMBINmune Bio35.20%PRMEPrime Medicine23.47%TILInstil Bio46.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRNAGreenLight Biosciences280151.68 million105.72 millionNot OptionableINMBINmune Bio1022.98 million14.37 millionOptionablePRMEPrime Medicine234131.29 million100.38 millionOptionableTILInstil Bio4106.56 million3.49 millionNo DataGRNA, TIL, PRME, and INMB HeadlinesRecent News About These CompaniesInstil Bio to Participate in the 2025 Jefferies Global Healthcare ConferenceMay 30 at 7:00 AM | globenewswire.comInstil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?May 29 at 1:06 PM | zacks.comWall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to TradeMay 29 at 11:00 AM | zacks.comInstil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF SuccessMay 25, 2025 | seekingalpha.comInstil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ...May 25, 2025 | morningstar.comInstil Bio stock price target cut to $105 by H.C. WainwrightMay 24, 2025 | uk.investing.comInstil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in ...May 24, 2025 | seekingalpha.comInstil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in ChicagoMay 23, 2025 | globenewswire.comInstil Bio Shares Jump on Trial Updates for Lung Cancer TreatmentMay 23, 2025 | marketwatch.comInstil Bio shares rise on immunotherapy trial updatesMay 23, 2025 | msn.comInstil Bio shares rise after updates on cancer trialsMay 23, 2025 | seekingalpha.comInstil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025May 22, 2025 | globenewswire.comInstil Bio, Inc. Progresses with Ongoing NSCLC Trials for AXN-2510/IMM2510 and Reports Q1 2025 Financial ResultsMay 13, 2025 | quiverquant.comInstil Bio Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 13, 2025 | globenewswire.comInstil Bio reports Q4 adjusted EPS ($1.08) vs. ($1.26) last yearMarch 4, 2025 | markets.businessinsider.comInstil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 4, 2025 | globenewswire.comInstil Bio: Time To Hop On The Summit Wave?February 24, 2025 | seekingalpha.comPrivate equity firms who hold 38% of Instil Bio, Inc. (NASDAQ:TIL) gained 34%, institutions profited as wellFebruary 20, 2025 | finance.yahoo.comJMP Securities Keeps Their Hold Rating on Instil Bio (TIL)February 13, 2025 | markets.businessinsider.comSummit Therapeutics (NASDAQ:SMMT) Stock Quotes, Forecast and News SummaryJanuary 24, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 High-Paying Dividend Stocks That Still Have Safe PayoutsBy Chris Markoch | May 27, 2025View 3 High-Paying Dividend Stocks That Still Have Safe PayoutsDoubt the Market? 3 Stocks to Rideout Fear, Uncertainty and DoubtBy Dan Schmidt | May 26, 2025View Doubt the Market? 3 Stocks to Rideout Fear, Uncertainty and Doubt3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsBy Leo Miller | May 27, 2025View 3 Beaten-Down Stocks Trading 50% Below Their 52-Week HighsPalantir: AI Leadership and Rising Analyst ExpectationsBy Chris Markoch | May 20, 2025View Palantir: AI Leadership and Rising Analyst Expectations3 Companies That Just Raised Dividends; 2 to Buy, 1 to AvoidBy Chris Markoch | May 19, 2025View 3 Companies That Just Raised Dividends; 2 to Buy, 1 to AvoidGRNA, TIL, PRME, and INMB Company DescriptionsGreenLight Biosciences NASDAQ:GRNAFUNR manufactures and sells all-natural juice beverages. Its products include pomegranate cranberry, wild berry and passion fruit-orange. The company was founded by Alex C. Procopio on July 22, 1980 and is headquartered in Las Vegas, NV.INmune Bio NASDAQ:INMB$7.46 +0.10 (+1.36%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$7.50 +0.04 (+0.52%) As of 05/30/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Prime Medicine NYSE:PRME$1.22 -0.05 (-3.57%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.20 -0.02 (-1.23%) As of 05/30/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Instil Bio NASDAQ:TIL$26.08 -4.27 (-14.07%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$26.80 +0.72 (+2.76%) As of 05/30/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
